多中心注册研究:EndoAnchor在EVAR近端移植物失败预防与治疗中的真实世界结局
该多中心回顾性注册研究纳入325例接受Heli-FX EndoAnchor系统(ESAR)治疗的患者,其中预防组234例(72%)在初次EVAR中预防近端移植物失败,治疗组91例(28%)治疗既往EVAR后的IA型内漏和/或移植物移位。中位随访42个月,预防组5年免于近端移植物失败率为90.2%(95%CI 85-95),治疗组为74.9%(95%CI 64-87)(P=.001)。预防组技术成功率和手术成功率均为100%,治疗组分别为97%和88%。
要点
- 预防性使用ESAR在初次EVAR中5年免于近端失败率达90.2%,治疗性使用为74.9%。
- 近端瘤颈长度<7 mm及以治疗为目的使用EndoAnchor与近端失败风险升高相关。
- 治疗IA型内漏时,EndoAnchor联合近端主动脉延伸物可提高成功率,术后造影持续IA型内漏为不良预后因素。
核心结论
- 在真实世界注册研究中,ESAR用于初次EVAR时高危近端瘤颈的辅助预防及既往EVAR后近端移植物失败的挽救治疗,两者成功率均较好。
- 预防性使用ESAR时,解剖性近端瘤颈长度<7 mm者结局较差。
- 治疗IA型内漏时,高达80%的病例获得良好结果,EndoAnchor联合近端主动脉延伸物时成功率更高,而完成造影时持续存在IA型内漏为不良预后因素。
研究设计与样本
- 多中心注册研究,回顾性数据分析,纳入2017-2025年接受ESAR治疗的患者325例。
- 预防组234例(72%)在初次EVAR中预防近端移植物失败,治疗组91例(28%)治疗既往EVAR后的IA型内漏和/或移植物移位。
- 终点包括技术成功、手术成功及免于近端移植物失败(新发IA型内漏、相关再干预、移植物移位)。
主要发现
- 技术成功率预防组100%、治疗组97%(P=.043),手术成功率分别为100%和88%(P<.001)。
- 中位随访42个月,5年免于近端移植物失败率预防组90.2%(95%CI 85-95),治疗组74.9%(95%CI 64-87)(P=.001)。
- 近端瘤颈长度<7 mm(HR 2.11;95%CI 1.18-4.56;P<.001)及以治疗为目的使用EndoAnchor(HR 3.48;95%CI 1.61-7.51;P<.001)与近端移植物失败风险升高相关。
- 治疗组中,单独使用EndoAnchor(未联合近端主动脉延伸物)(HR 4.00;95%CI 1.19-8.65;P<.001)及完成造影时持续IA型内漏(HR 15.9;95%CI 10.5-23.0;P<.001)与近端失败风险升高相关。
关键数值与推荐
- 预防组5年免于近端移植物失败率90.2%(95%CI 85-95),治疗组74.9%(95%CI 64-87)(P=.001)。
- 预防组技术成功100%、手术成功100%;治疗组技术成功97%、手术成功88%。
- 近端瘤颈长度<7 mm的HR为2.11(95%CI 1.18-4.56;P<.001);以治疗为目的使用EndoAnchor的HR为3.48(95%CI 1.61-7.51;P<.001)。
- 治疗组单独使用EndoAnchor的HR为4.00(95%CI 1.19-8.65;P<.001);完成造影持续IA型内漏的HR为15.9(95%CI 10.5-23.0;P<.001)。
临床怎么用
- 对于近端瘤颈高危的初次EVAR患者,可考虑辅助使用ESAR以预防近端移植物失败。
- 治疗既往EVAR后的IA型内漏时,EndoAnchor宜联合近端主动脉延伸物使用,并应避免完成造影时残留IA型内漏。
- 近端瘤颈长度<7 mm的患者预防性使用ESAR结局较差,需个体化评估。
局限性
- 为回顾性注册研究,可能存在选择偏倚。
- 预防组与治疗组基线特征可能不可比,影响组间比较。
- 未来需开展对比研究以进一步明确ESAR在预防和治疗中的临床疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the outcomes of the Heli-FX EndoAnchor system (ESAR) in the prevention and treatment of proximal endograft failure after endovascular aneurysm repair (EVAR). METHODS: We conducted a retrospective data analysis from a multicenter registry of patients treated by ESAR (2017-2025). In the prevention group (PG), endoanchors were used to prevent proximal endograft failure during primary endovascular repair (EVAR). In the treatment group (TG), endoanchors were used to treat a type IA endoleak and/or migration after a previous EVAR. End points were technical success, procedural success, and freedom from proximal endograft failure (new-onset type IA endoleak, related reintervention, endograft migration). RESULTS: There were 325 patients, 234 (72%) in the PG and 91 (28%) in the TG. Technical success was 100% in the PG and 97% in TG (P = .043), with a procedural success of 100% vs 88% (P < .001). After 5 years of follow-up (median, 42 months), freedom from proximal endograft failure was 90.2% [95% confidence interval (CI), 85-95] in the PG and 74.9% (95% CI, 64-87) in the TG (P = .001). Neck length <7 mm [hazard ratio (HR), 2.11; 95% CI, 1.18-4.56; P < .001] and use of endoanchors as a treatment (HR, 3.48; 95% CI, 1.61-7.51; P < .001) had a higher risk of proximal endograft failure. In the TG, the use of endoanchors alone (without a proximal aortic extension; HR, 4.00; 95% CI, 1.19-8.65; P < .001) and the persistence of a type IA endoleak at the completion angiography (HR, 15.9; 95% CI, 10.5-23.0; P < .001) were associated with a higher risk of proximal failure. CONCLUSIONS: In this real-world registry, ESAR was used as an adjunct during primary EVAR in patients with a hostile proximal neck and as a salvage treatment of proximal endograft failure after a previous EVAR, with favorable success rates in both settings. In the preventive setting, outcomes were less favorable when the anatomical proximal neck length was <7 mm. In the treatment of type IA endoleak, favorable results were obtained in up to 80% of cases, with a higher success rate when endoanchors were combined with a proximal aortic extension, and the persistence of a type IA endoleak on the completion angiogram was a negative prognostic factor. Future comparative studies are necessary to better clarify the clinical efficacy of ESAR in a prevention and treatment setting.
引用
- Antonello M, Marrocco S, Pratesi G, et al. Real-world outcomes of endoanchors in the prevention and treatment of proximal endograft failure in a multicenter registry. J Vasc Surg. 2026. PMID: 42810698. doi:10.1016/j.jvs.2026.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。